Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)

Real-time Quote. Real-time Tradegate - 03/23 08:59:58 pm
70.549 EUR   +1.36%
08:37a UCB : U.S. Patent and Trademark Office confirms validity of patent &..
03/17 UCB : Brussels - Transparency notifications
03/16 UCB : Transparency notifications
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

UCB : Acquisition of own shares in the framework of employees’ long-term incentive plans

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/04/2011 | 08:05pm CET

BRUSSELS, Belgium, 4 August 2011 – 19:30 (CET) – regulated information - In application of art. 207 of the Royal Decree executing the Company Code, UCB publishes having acquired 7,600 UCB shares on the Brussels stock exchange on the dates and at the prices indicated hereunder:

Date

Price EUR

Amount

03/08/2011

31.6376

600

03/08/2011

31.20

2,000

02/08/2011

31.48

2,500

29/07/2011

32.23

500

29/07/2011

32.49

2,000

These shares were immediately distributed to the employees who have exercised share options that had been granted to them in the framework of existing Company’s share option plans of which the detail is given in UCB annual report.

UCB S.A. - Allée de la Recherche, 60 - 1070 Bruxelles - RPM 0403.053.608

For further information antje.witte@ucb.com

Antje Witte, Investor Relations, UCB

T +32.2.559.9414,

Michael.tuck-sherman@ucb.com

Michael Tuck-Sherman, Investor Relations, UCB

T +32.2.559.9712,

About UCB ) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8 500 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2010. UCB is listed on Euronext Brussels (symbol: UCB). www.ucb.com

UCB, Brussels, Belgium (

Forward-looking statements

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.

Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on UCB
08:37a UCB : U.S. Patent and Trademark Office confirms validity of patent …
03/17 UCB : Brussels - Transparency notifications
03/16 UCB : Transparency notifications
03/10 UCB : Acquisition of own shares
03/09 UCB : Researchers from UCB S.A. Report New Studies and Findings in the Area of E..
03/09 UCB : Transparency notification
03/09 SCHEDULES OF CONTROLLED SUBSTANCES : Placement of Brivaracetam Into Schedule V
03/08 UCB : Transparency notification
03/07 UCB : Transparency notification
03/06 UCB : New CIMZIA (certolizumab pegol) data in moderate-to-severe plaque psoriasi..
More news
Sector news : Pharmaceuticals - NEC
11:53a TEVA PHARMACEUTICAL INDUSTRIES : Pharm says media reports of up to 6,000 layoffs..
03/22 MYLAN : recalls 81,000 EpiPens outside U.S. after reports of failure
03/21DJSANOFI'S PRESCRIPTION FOR GROWTH : Drug Sales in the Middle Kingdom
03/20 FTSE rises to record close after Article 50 trigger date set
03/17DJPFIZER : Files 8K - Other Events
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
03/21 UCB Needs Clinical Success To Drive Upside
02/24 UCB S.A. 2016 Q4 - Results - Earnings Call Slides
02/24 UCB's (UCBJF) CEO Jean-Christophe Tellier on Q4 2016 Results - Earnings Call ..
02/23 UCB S.A. reports FY results
01/10 RHEUMATOID ARTHRITIS : The Big 3 And The Future
Advertisement
Financials (€)
Sales 2017 4 302 M
EBIT 2017 920 M
Net income 2017 609 M
Debt 2017 596 M
Yield 2017 1,80%
P/E ratio 2017 20,59
P/E ratio 2018 16,96
EV / Sales 2017 3,29x
EV / Sales 2018 2,99x
Capitalization 13 538 M
More Financials
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders
Full-screen chart
Technical analysis trends UCB
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 76,4 €
Spread / Average Target 9,8%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Gerhard N. Mayr Chairman
Mark D. McDade Chief Operating Officer & Executive Vice President
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Loew-Friedrich Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
UCB14.27%14 620
JOHNSON & JOHNSON9.59%342 277
ROCHE HOLDING LTD.7.52%217 164
PFIZER INC.6.13%205 273
NOVARTIS AG0.47%194 072
MERCK & CO., INC.7.86%174 344
More Results